GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted FCF per Share

Novartis AG (BUE:NVS) Cyclically Adjusted FCF per Share : ARS1,410.49 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novartis AG's adjusted free cash flow per share for the three months ended in Mar. 2024 was ARS908.884. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS1,410.49 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average Cyclically Adjusted FCF Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 2.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novartis AG was 4.00% per year. The lowest was 0.50% per year. And the median was 1.60% per year.

As of today (2024-06-02), Novartis AG's current stock price is ARS31040.00. Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS1,410.49. Novartis AG's Cyclically Adjusted Price-to-FCF of today is 22.01.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 21.84. The lowest was 14.52. And the median was 17.78.


Novartis AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted FCF per Share Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.03 174.01 243.66 428.85 1,327.09

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 527.92 684.00 1,095.96 1,327.09 1,410.49

Competitive Comparison of Novartis AG's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.



Novartis AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=908.884/107.3549*107.3549
=908.884

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 15.645 101.517 16.545
201409 20.616 101.247 21.860
201412 30.405 100.704 32.413
201503 7.132 100.339 7.631
201506 13.850 100.464 14.800
201509 18.095 99.785 19.468
201512 34.112 99.386 36.847
201603 10.146 99.475 10.950
201606 28.367 100.088 30.427
201609 28.703 99.604 30.937
201612 37.214 99.380 40.200
201703 19.244 100.040 20.651
201706 42.092 100.285 45.059
201709 43.337 100.254 46.407
201712 46.786 100.213 50.120
201803 31.593 100.836 33.636
201806 73.544 101.435 77.836
201809 101.016 101.246 107.112
201812 100.375 100.906 106.790
201903 65.412 101.571 69.137
201906 102.304 102.044 107.629
201909 194.633 101.396 206.072
201912 150.483 101.063 159.851
202003 110.761 101.048 117.675
202006 208.530 100.743 222.216
202009 163.122 100.585 174.102
202012 212.500 100.241 227.581
202103 101.176 100.800 107.756
202106 296.608 101.352 314.175
202109 380.535 101.533 402.357
202112 297.287 101.776 313.584
202203 75.837 103.205 78.886
202206 345.262 104.783 353.737
202209 541.650 104.835 554.671
202212 561.371 104.666 575.792
202303 478.593 106.245 483.594
202306 591.122 106.576 595.445
202309 1,583.629 106.570 1,595.300
202312 614.083 106.461 619.238
202403 908.884 107.355 908.884

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Novartis AG  (BUE:NVS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=31040.00/1410.49
=22.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 21.84. The lowest was 14.52. And the median was 17.78.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novartis AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BUE:NVS) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (BUE:NVS) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Moser Wealth Advisors, LLC

By GuruFocus Research GuruFocus Editor 08-03-2022

Novartis' Strategic Plan Brings Many Plusses

By Barry Cohen 09-28-2022